Kurma Growth Opportunities and Eurazeo leads a EUR 93 million funding round for PanTera to enhance the large-scale production of actinium-225, a vital isotope for targeted cancer treatments.

Target Information

PanTera, a Belgian producer of radioisotopes, was established in 2022 with the primary objective of facilitating large-scale production of actinium-225 (225Ac), an essential component for developing targeted cancer therapies. The recent funding round, which raised EUR 93 million, will predominantly finance the construction of a cutting-edge production facility in Belgium, positioning PanTera to alleviate the ongoing global shortage of this vital isotope.

This shortage is particularly pressing due to the increasing demand for actinium-225 in Targeted Alpha Therapy, a promising cancer treatment that safely delivers radioisotopes to effectively destroy cancer cells while minimizing damage to healthy tissue. As pharmaceutical companies expand their clinical trials and aim for regulatory approvals across various cancers, a reliable and sustainable production method for actinium-225 has become critical.

Industry Overview in Belgium

Belgium has established itself as a significant player in the life sciences sector, known for its strong pharmaceutical and biotechnology industries. With a well-developed infrastructure and a collaborative ecosystem involving research institutio